Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 719 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Tract Clear all

Conditions: Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis, Primary Sclerosing Cholangitis
Interventions: Nemolizumab-ilto; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Primary Biliary Cirrhosis
Interventions: Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more

Conditions: Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more

Conditions: Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastrointestinal Cancer, Liver and Intrahepatic Biliary Tract Cancer, Lung Cancer, Metastatic Cancer, Pancreatic Cancer, Rectal Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: radionuclide imaging, positron emission tomography, laboratory biomarker analysis, pharmacological study, Cu 64 anti-CEA monoclonal antibody M5A IV; Procedure · Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Advanced Biliary Tract Cancer
Interventions: Nanoliposomal Irinotecan, Leucovorin, Fluorouracil; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • St Louis, Missouri + 1 more

Conditions: Bile Duct Disorder, Endocrine Pancreas Disorder
Interventions: Endoscopic Retrograde Cholangiopancreatography, Interview, Laryngeal Mask Airway; Procedure · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Choledocholithiasis, Biliary Obstruction
Interventions: Cholangioscopy, Spyglass DS Cholangioscope; Procedure · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer
Interventions: Cisplatin, Erlotinib, Gemcitabine; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: San Francisco, California • Albuquerque, New Mexico

Conditions: Gallbladder Diseases
Interventions: Not listed
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
Interventions: Trametinib, Hydroxychloroquine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: LUM001; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: La Jolla, California • Sacramento, California • Aurora, Colorado + 2 more

Conditions: Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 2 Years to 25 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Primary Biliary Cholangitis
Interventions: EDP-305 1 mg, EDP-305 2.5 mg, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 40
States / cities: Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more

Conditions: Biliary Atresia
Interventions: Filgrastim; Drug
Lead sponsor: Holterman, Ai-Xuan, M.D.; Individual
Eligibility: 14 Days to 180 Days
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Appendix Cancer, Stomach Cancer, Gallbladder Cancer, Liver Cancer, Small Intestine Cancer, Large Intestine Cancer, Anal Cancer, Biliary Tract Cancer, Gastrointestinal Stromal Cancer
Interventions: Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration, Yoga Skills Training, Attention Control, Actigraphy Assessment; Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Nashville, Tennessee

Conditions: Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Immune Checkpoint Inhibitor; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
Interventions: Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin; Drug · Biological
Lead sponsor: Intima Bioscience, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Biliary Tract Neoplasms, Biliary Duct Obstruction, Unresectable Pancreatic Cancer, Periampullary Cancer, Periampullary Carcinoma Non-Resectable
Interventions: Endoscopic Ultrasound Guided Biliary Drainage, ERCP; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Common Bile Duct Neoplasms, Non-Neoplastic Bile Duct Disorder
Interventions: AI model classification, DSOC endoscopist experts' classification; Diagnostic Test
Lead sponsor: Instituto Ecuatoriano de Enfermedades Digestivas; Other
Eligibility: 18 Years to 79 Years
Enrollment: 170 participants
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Houston, Texas

Conditions: HER2-positive Advanced Solid Tumor
Interventions: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole; Biological · Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Cerritos, California • Los Angeles, California • San Diego, California + 29 more

Conditions: Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer, Cancer of Gallbladder
Interventions: Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin, Carboplatin, Capecitabine, 5FU, Liver transplantation; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Cholecystitis
Interventions: Percutaneous cholecystostomy, EUS-guided gallbladder drainage; Procedure
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders

Prospective Evaluation of the Ability of Spyglass Cholangioscopy to Facilitate Radiation Free ERCP

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

Comparing the Outcomes of Laparoscopic Cholecystectomy vs. Robotic Cholecystectomy

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis in Children

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

Programs To Support You During Chemotherapy

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

EUS BD vs ERCP TP for Pancreatic Cancer

Artificial Intelligence for Digital Cholangioscopy Neoplasia Diagnosis

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Randomized Trial of Percutaneous vs. Endoscopic Gallbladder Drainage